24th Nov 2011 12:00
Block listing six monthly return
November 24, 2011 - Shire plc
Name of applicant: Shire plc Name of scheme: 2000 Executive Share Option Scheme Period of return: From: May 23, 2011 To: November 22, 2011
Balance of unallotted securities under 3,709,681 scheme(s) from previous return: Plus: The amount by which the block Nil scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/ 160,909 allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not 3,548,772 yet issued/allotted at end of period:
Name of applicant: Shire plc Name of scheme: Shire Sharesave Scheme Period of return: From: May 23, 2011 To: November 22, 2011
Balance of unallotted securities under 5,392 scheme(s) from previous return: Plus: The amount by which the block Nil scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/ Nil allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not 5,392 yet issued/allotted at end of period:
The remaining 78,597 securities under the Shire plc 1996 Executive Share Option Scheme and the remaining 3,873 securities under the Biochem Pharma Stock Option Plan have lapsed and these shares have therefore been cancelled.
Name of contact: Tony Guthrie, Deputy Company Secretary Address of contact: Hampshire International Business Park Basingstoke, Hampshire, RG24 8EP Telephone number of contact: 01256 894746
For further information please contact:
Investor Eric Rojas [email protected] +1 781 482 0999 Relations Sarah Elton-Farr [email protected] +44 1256 894157
Notes to editors
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release
www.shire.com
XLONRelated Shares:
Shire